Back to top
more

uniQure (QURE)

(Delayed Data from NSDQ)

$4.53 USD

4.53
354,544

-0.01 (-0.22%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $4.53 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QURE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

uniQure N.V. [QURE]

Reports for Purchase

Showing records 1 - 20 ( 153 total )

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 1

03/01/2024

Company Report

Pages: 8

Huntington''s Program Pathway to Emerge in 2024; Multiple Gene Therapies Advancing to Phase 1/2; Price Target Down to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 2

01/19/2024

Company Report

Pages: 7

Year of Execution Should Pave Path Forward For Multiple Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 3

12/19/2023

Daily Note

Pages: 3

Long-Term AMT-130 Data Shows Clinical Improvement; Disappoints on Target Engagement; Regulatory Path to Emerge in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 4

11/08/2023

Company Report

Pages: 9

3Q23 Results; Hungtington''s Program Phase 1/2 Data Expected in 4Q23; Early Stage Pipeline Progressing to Study Starts

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 5

10/13/2023

Company Report

Pages: 7

Restructuring Improves Financial Position Ahead of Next Updates on Huntington''s and Preclinical Gene Therapy Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 6

08/02/2023

Company Report

Pages: 9

Clinical Updates on Huntington''s Program Expected in 4Q23; Early-Stage Pipeline Progressing; Lowering PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 7

06/21/2023

Daily Note

Pages: 3

AMT-130 Update; Demonstrates Clinical Improvement; Disappoints on Target Engagement; Regulatory Path to Emerge in 2024

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 8

05/16/2023

Company Report

Pages: 8

Partial Monetization of HEMGENIX Royalties Extends Cash Runway to 2Q26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 9

05/10/2023

Company Report

Pages: 8

1Q23 Results; Pipeline Progressing; Potential Blockbuster Huntington''s Program Nearing Phase 1/2 Data Update; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 10

03/07/2023

Company Report

Pages: 9

4Q22 Results; HEMGENIX Launch, Key Pipeline Updates on Huntington''s Disease Programs in the Spotlight for 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 11

12/29/2022

Daily Note

Pages: 3

Read-Through From Pfizer''s Phase 3 Hem-B Data Looks Positive For HEMGENIX

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 12

12/15/2022

Company Report

Pages: 9

Spotlight on HEMGENIX at ASH Demonstrates Durable Safety and Efficacy of Treatment in Hem-B; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 13

12/01/2022

Company Report

Pages: 40

HEMGENIX Approved in Hem-B; R&D Event Highlights Platform Progress and Advancement of Epilepsy Program; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 35.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 14

11/03/2022

Company Report

Pages: 8

3Q22 Results; Resumes High-Dose AMT-130 Enrollment in Huntington''s Program; EtranaDez on Track for FDA Approval in 4Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 15

08/09/2022

Company Report

Pages: 8

Sell-Off Tied to Adverse Events in High Dose Cohort of Huntington''s Program Appears Overdone

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 16

06/24/2022

Company Report

Pages: 8

AMT-130 Demonstrates Robust Target Engagement in Huntington''s Disease Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 17

05/04/2022

Company Report

Pages: 9

1Q22 Results; EtranaDez on Track For Potential Approval in 2023; Next Update on Huntington''s Program Expected in 2Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 18

03/01/2022

Company Report

Pages: 8

4Q21 Results; EtranaDez Nearing Potential Submissions; Huntington''s Program, Preclinical Programs Advancing on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 19

12/16/2021

Daily Note

Pages: 4

Sell-off Tied to Initial Phase 1/2 Data in Huntington''s Program Is Overdone, in Our View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: uniQure N.V.

Industry: Medical - Biomedical and Genetics

Record: 20

12/09/2021

Daily Note

Pages: 3

Positive Hem-B Update; Pivotal HOPE-B Trial Achieves Primary Endpoint

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party